SEC Form 4 · accession 0001209191-17-021807
ARENA PHARMACEUTICALS INC · ARNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Preston Klassen
Officer — EVP and CMO
Period of report
Mar 20, 2017
Accepted (ET)
Mar 20, 2017 · 5:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001080709
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buyF1 | $1.50 | Mar 20, 2017 | A | 1,293,500 | A | — | Mar 20, 2024 | Common Stock | 1,293,500 | 1,293,500 | D |
Explanation of responses
- F1The options vest over four years, with 25% vesting on March 20, 2018, and the remainder of the options vesting monthly over the three years thereafter in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.